Equity grants to Regeneron (REGN) director David P. Schenkein reported

Rhea-AI Filing Summary

Regeneron Pharmaceuticals director David P. Schenkein reported new equity awards. On 01/02/2026, he acquired 1,962 non-qualified stock options with an exercise price of $772.76 per share, each option linked to Regeneron common stock. A portion of these options becomes exercisable on the date of the company’s first annual shareholder meeting following the grant, with the remainder vesting on the first anniversary of the grant date.

He also acquired 155 time-based restricted stock units, each representing a contingent right to receive one share of Regeneron common stock. Following this grant, he beneficially owned 603 shares of common stock directly.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Schenkein David P

(Last) (First) (Middle)

777 OLD SAW MILL RIVER ROAD

(Street)

TARRYTOWN NY 10591

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
REGENERON PHARMACEUTICALS, INC. [ REGN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/02/2026		A(1)		155	A	$0.0	603	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Non-Qualified Stock Option (right to buy)	$772.76	01/02/2026		A		1,962		(2)	01/02/2036	Common Stock	1,962	$0.0	1,962	D

Explanation of Responses:

1. Reflects an acquisition of time-based vesting restricted stock units each representing a contingent right to receive one share of the Issuer's common stock.

2. On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that has passed from the date of grant shall then become exercisable, and the remainder shall become exercisable on the first anniversary of the date of grant.

	/s/ David P. Schenkein	01/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did REGN director David P. Schenkein report?

David P. Schenkein, a director of Regeneron Pharmaceuticals, reported receiving new equity awards consisting of non-qualified stock options and time-based restricted stock units tied to the company’s common stock.

How many Regeneron (REGN) stock options were granted to David P. Schenkein?

He was granted 1,962 non-qualified stock options, each giving him the right to buy one share of Regeneron common stock at an exercise price of $772.76 per share.

When do David P. Schenkein’s new Regeneron stock options vest?

A portion of the options becomes exercisable on the date of Regeneron’s first annual meeting of shareholders after the grant date, with the remaining options becoming exercisable on the first anniversary of the grant date.

What restricted stock units did David P. Schenkein receive from Regeneron?

He acquired 155 time-based vesting restricted stock units, each representing a contingent right to receive one share of Regeneron common stock, subject to vesting conditions.

How many Regeneron shares does David P. Schenkein own after this Form 4 transaction?

After the reported transaction, David P. Schenkein beneficially owned 603 shares of Regeneron common stock directly.

Is David P. Schenkein a 10% owner of Regeneron Pharmaceuticals (REGN)?

No. In this filing, David P. Schenkein is identified as a director of Regeneron and is not marked as a 10% owner.